Oncology Based In-vivo CRO Market Is Predicted To Grow Quickly Due To The Increasing Incidence Of Cancer Till 2025: Grand View Research, Inc.
The global oncology based in-vivo CRO
market is expected to reach USD 1.5 billion by 2025, according to a
new report by Grand View Research, Inc. The use of Contract Research
Organization (CRO) oncology services helps the manufacturers/sponsors to
provide complete attention on the production capacity and at enhancing their
in-house processes.
Furthermore, the pressure from
the increasing competition due to patent expirations, rapid growth of generics,
and introduction of biosimilar equivalents are propelling the pharmaceutical
companies to take the aid of such organizations. Hence, it can be predicted
that the oncology based in-vivo CRO market may witness
lucrative growth over the forecast period.
Another factor propelling growth
is the increasing incidence of cancer, and high failure rate of existing
treatment options. According to statistics published by the World Health
Organization (WHO), approximately 8.2 million deaths are recorded each year
from cancer, which accounts for 13.0% deaths worldwide.
Browse full research report on Oncology Based In-vivo CRO
Market: http://www.grandviewresearch.com/industry-analysis/oncology-based-in-vivo-cro-market
Further key findings from the study suggest:
- Based on indication, solid tumors are expected to
dominate the market as of 2016. Furthermore, it is anticipated to grow at
the fastest CAGR owing to the factors such as growing incidence rate,
augmenting research for tumors in organs such as breast, and liver, and
technological advancement offered by key industry players.
- Solid tumors are analyzed by means of models such as
xenograft, Patient Derived Xenografts (PDX), and syngeneic. The PDX models
are expected to witness lucrative growth over the forecast period and
capture over 40.0% of the market share by 2025.
- Geographic expansion into Asia Pacific countries by
well-established players is anticipated to promote the fastest growth for
the region. India is one the most lucrative country owing to presence of
service tax exemption and venture capital based funding for CROs.
- Few of the industry players for the oncology
based in-vivo CRO market are The Jackson Laboratory,
Covance, Taconic Biosciences, Charles River Laboratory, EVOTEC, Wuxi
AppTec, and ICON Plc.
- A common trend observed is the rising partnerships
among CROs to offer bundle packages of services to sponsors. For instance,
In May 2017, CRL International, Inc. announced their partnership with
OcellO, established in Netherlands. According to this partnership, CRL
would be utilizing the latter’s PDX model capabilities in order to expand
their oncology based drug discovery service portfolio.
Browse more reports of this category by Grand View
Research: http://www.grandviewresearch.com/industry/pharmaceuticals
Grand View Research has segmented the global oncology
based in-vivo CRO market on the basis of indication, and
region:
Global Oncology Product Outlook (Revenue, USD Million, 2014
- 2025)
- Blood
cancer
- Solid
tumors
- Syngeneic
model
- Patient
Derived Xenograft (PDX)
- Xenograft
- Others
Oncology in-vivo CRO Regional Outlook
(Revenue, USD Million, 2014 - 2025)
- North
America
- U.S.
- Canada
- Europe
- UK
- Germany
- Asia
Pacific
- Japan
- China
- Latin
America
- Brazil
- Argentina
- Middle
East and Africa (MEA)
- South
Africa
- Saudi
Arabia
Access Press Release
By Grand View Research: http://www.grandviewresearch.com/press-release/global-oncology-based-in-vivo-cro-market
About Grand View Research
Grand View Research, Inc. is a
U.S. based market research and consulting company, registered in the State of
California and headquartered in San Francisco. The company provides
syndicated research reports, customized research reports, and consulting
services. To help clients make informed business decisions, we offer market
intelligence studies ensuring relevant and fact-based research across a range
of industries, from technology to chemicals, materials and healthcare.
Comments
Post a Comment